natgillin/translations-raw huggingface dataset:
in case of repair or adjustment of the dispensing assembly. 
u slučaju popravka ili podešavanja sklopa za točenje.
Composition according to any one of the preceding claims, wherein the total nitrogen content of the composition, as determined by Nitrogen Determination (Kjeldahl Method), Method II (FNP 5), is less than 20%, by weight of dry matter, preferably is within the range of 0.1 to 15% by weight of dry matter. 
Pripravak prema bilo kojem od prethodnih zahtjeva, naznačen time, što ukupni sadržaj dušika u pripravku, određen pomoću određivanja dušika (postupak po Kjeldahlu), postupak II (FNP 5), je manji od 20%, po masi suhe tvari, poželjno je unutar opsega od 0,1 do 15% po masi suhe tvari.
a second pump (4) installed in the fuel gas supply line to compress LNG from the LNG tank at a high pressure and supply the compressed LNG to the high-pressure gas injection engine; 
Sustav dobave pogonskog plina za brod prema zahtjevu 1, naznačen time da su sredstva za komprimiranje konfiguriranja za izvlačenje LNG iz spremnika LNG (1), stlačivanje izvučenog LNG kod visokog pritiska, te za dovođenje stlačenog LNG prema visokotlačnom plinskom injekcijskom motoru.
The clarithromycin, lactose, starch and croscarmellose Na were mixed in a 2.5 L high-shear VG5 Glatt granulator for 5 minutes with an impeller set at 350 rpm and chopper set at 2000 rpm. 
Klaritromicin, laktoza, škrob i kroskarmeloza natrij se miješaju u 2,5 litarskom visoko-smičnom VG5 Glatt granulatoru tijekom pet minuta uz impeler namješten na 350 okretaja po minuti i rotacioni sjekač namještenu na 2000 okretaja po minuti.
The transgenic plant of claim 13, wherein the polypeptide is encoded by a nucleotide sequence set forth in SEQ ID NO:2. 
nukleotidnu sekvencu koja kodira polipeptid otporan na bolest koji je prikazan u SEQ ID NO: 14, i
J independently is hydrogen; methyl; or fluoro; 
J neovisno jest vodik; metil; ili fluor;
forms alpha and beta of the hydrogen succinate salt of Compound 
Kristalinična vodik sukcinatna sol Spoja I prema zahtjevu 1.
The method is for example as follows: the lower layer 218 is provided by direct injection in a mold. 
Postupak je primjerice sljedeći: donji sloj 218 se izrađuje izravnim injektiranjemu kalup.
Patients found that the administration of thyroid hormones by using an inhaler (accurate dose well adapted to their needs) is more comfortable than the oral-tablet administration (tablets show less accurate dose than the administration via inhaler). 
Pacijenti su otkrili da je primjena tiroidnih hormona upotrebom inhalatora (točna doza dobro prilagođena njihovim potrebama) ugodnija nego oralna primjena tableta (tablete su pokazale manje točne doze nego primjena putem
Process according to claim 1, wherein an amount of other materials up to a maximum of 35% by weight can be added to the mixture formed in said step b) in order to confer special aesthetic effects to the final product. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da se u smjesu nastalu u navedenom koraku b) može dodati količina drugih materijala do najviše 35% težinski, kako bi se konačnom proizvodu dali posebni estetski efekti.
The method of items 48-50, wherein the antigen recognition complex is constitutively expressed on the surface of the cell. 
T-stanica prema zahtjevu 6 ili zahtjevu 7, naznačena time da je ko-stimulacijski ligand konstitutivno eksprimiran na površini T-stanice.
Further fresh palladium on carbon (4.0g) and acetic acid (20ml) added and the reaction mixture was stirred under an atmosphere of hydrogen for a further 16 hours. 
Doda se svježi paladij na ugljiku (4,0 g) i octena kiselina (20 ml), a reakcijsku smjesu miješa u atmosferi vodika još 16 sati.
Another treatment regimen for IL-2 is to administer 6 x 105 IU per kg by intravenous bolus every 8 hours, for 14 doses over 5 days, with a second treatment being given after a 9 day rest period. 
Drugi je režim liječenja za IL-2 da se daje 6310? TU po kg intravenozno u bolusu svakih 8 sati, za 14 doza tijekom 5 dana, s drugim liječenjem koje se daje nakon perioda od 9 dana odmora.
The process according to any of claims 1-14 with the additional step of adding aqueous HBr to the product said product optionally being in a purified form, to obtain the corresponding hydrobromic acid salt. 
Postupak prema zahtjevu 23, pri čemu se dobivena smjesa zagrijava do refluksa 4-6 sati, i nakon čega slijedi sljedeći korak gdje dobiveni produkt dalje reagira s vodenim HBr da se dobije odgovarajuća adicijska sol bromovodične kiseline.
It is believed that the martensitic transformation can be activated either by physical means (e.g. 
Vjeruje se da se martenzitsku transformacija može aktivirati na fizikalni način (npr.
a 5' wing segment consisting of three linked nucleosides; and 
’ segment „krila“ koji se sastoji od tri vezana nukleozida; i
The anti-CTLA-4 antibody and 4'-Demethylepipodophyllotoxin 9-[4,6-O-(R)-ethylidene-B-D-glucopyranaside], 4'-(dihydrogen phosphate) or a pharmaceutically acceptable salt, solvate, or hydrate thereof, for the use according to any one of Claims 1 to 8, wherein said cancer treatment further comprises an anti-proliferative cytotoxic agent either alone or in combination with radiation therapy. 
Anti-CTLA-4 antitijelo i 4'-Demetilpipodofilotoksin 9-[4,6-O-(R)-etiliden-B-D-glukopiranazid], 4'-(dihidrogen fosfat) ili njegova farmaceutski prihvatljiva sol, solvat, ili hidrat, za primjenu prema bilo kojem od patentnih zahtjeva 1 do 8, gdje navedeno liječenje raka dalje sadrži anti-proliferativni citotoksični agens ili sam ili u kombinaciji sa radioterapijom.
A process as claimed in claim 1 wherein the step of extruding the flour mixture is followed by the steps of adding the gelling agent to the extruder, and is followed by the step of extruding the resultant mixture of flour mixture and gelling agent. 
pri čemu nakon koraka ekstruzije smjese slijedi korak dodavanja sredstva za geliranje u ekstruder, nakon čega slijedi korak ekstruzije smjese dobivene od smjese brašna i sredstva za geliranje;
When the driving spring 17 is axially tensioned, the holder 16, with the container 13 and the feed tube 19, is moved downwards as shown in the illustrations and fluid 12 is sucked out of the container 13 into the pressure chamber 21 of the pressure generator 15 via the non-return valve 20. 
Kad je opruga 17 napregnuta aksijalno, držač 16, sa spremnikom 13 i cjevčicom za punjenje 19 se pomakne prema dolje, kako je prikazano na slikama, i fluid 12 se preko nepovratnog ventila 20 usisa iz spremnika 13 u tlačnu komoru 21 generatora pritiska 15.
A representative synthesis is shown in Reaction Scheme IV using alcohol (AG′). 
Primjer sinteze je prikazan u Reakcijskoj Shemi IV uporabom alkohola (AG').
Also provided is the use of a composition comprising an antigen in the preparation of a medicament for stimulating an immune response against the antigen, wherein the antigen is associated with a binding agent having affinity for CLEC9a. 
Uporaba sastava prema bilo kojem od zahtjeva 1 do 5, naznačena time, da je za proizvodnju lijeka za stimuliranje imunološke reakcije protiv antigena ili za uporabu u induciranju tolerancije prema antigenu.
a C6-14 aryl group optionally substituted by the same or different 1 to 5 substituents selected from the above-mentioned group B, a C6-14 aryl-C1-6 alkyl group (wherein C6-14 aryl is optionally substituted by the same or different 1 to 5 substituents selected from the above-mentioned group B), or 
C1.10 alkil skupina, CÂ«.1a aril skupina opcijski supstituirana sa 1 do 5 istih ili različitih supstituenata izabranih iz gore navedene skupine B, CÂ«_14 aril-C,.galkil skupina (gdje C4.14 aril je opcijski supstituiran sa 1 do 5 istih 1li različitih supstituenata izabranih iz gore navedene skupine B) ili
Table 16 Number of animals 
Broj međunarodne objave:
This invention also provides a unit dose of 0.5 ml of an aqueous pharmaceutical solution which contains in solution 20 mg glatiramer acetate and 20 mg mannitol for use in reducing the frequency of relapse in a human patient who experienced a first clinical episode consistent with multiple sclerosis and who has a high risk of developing clinically definite multiple sclerosis (CDMS). 
Jedinična doza prema bilo kojem od patentnih zahtjeva 1-4, naznačena time, da jest za uporabu u liječenju ljudskog pacijenta koji je imao prvu kliničku epizodu koja odgovara multiploj sklerozi i za kojega je ustanovljeno da ima veliki rizik za razvoj klinički definitivne multiple skleroze (CDMS).
The method according to any of the preceding claims, wherein B is true and wherein the decoder uses at least one x86 processor whose instruction set includes streaming single instruction multiple data extensions (SSE) comprising vector instructions, and wherein the time domain downmixing includes running vector instructions on at least one of the one or more x86 processors. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da dekoder (200) koristi barem jedan x86 procesor čiji skup instrukcija sadrži niz SSE instrukcija SIMD tipa (SIMD, eng. single instruction multiple data – jednostruka instrukcija, višestruki podaci) koje sadrže vektorske instrukcije, te time da svođenje kanala u vremenskoj domeni sadrži izvođenje vektorskih instrukcija na barem jednom od jednog ili više x86 procesora.
The method of claim 8 wherein (a) is 2.5 to 10 g ae/ha of a compound of formula (I) or an agriculturally acceptable salt or ester thereof, and (b) is 60 to 240 g ai/ha of flufenacet. 
Postupak u skladu s patentnim zahtjevom 8, naznačen time što je (a) 2,5 do 10 g ae/ha spoja formule (I), ili njegove agrikulturno prihvatljive sol ili estera, i (b) je 60 do 240 g ai/ha flufenaceta.
The compound, depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle. 
Spoj, ovisno o upotrijebljenom vehikulumu i koncentraciji, može biti bilo suspendiran ili otopljen u vchikulumu.
A method of claim 15 wherein the cancer is selected from a group consisting of: ovarian cancer, pancreatic cancer, breast cancer, prostate cancer and leukemia. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 11, naznačen time što se rak bira iz skupine koju čine: rak jajnika, rak gušterače, rak dojke, rak prostate i leukemija.
The compound of claim 1, wherein R4 is an optionally substituted piperidinyl, cyclohexyl, phenyl, 
Spoj prema zahtjevu 1, naznačen time, da R4je opcijski supstituirani piperidinil, cikloheksil, fenil, [image]
Shower tray as claimed in claim 13, wherein a protruding membrane is arranged between the tile and foam plate. 
Tuš kada u skladu s patentnim zahtjevom 10, naznačena time što se između obložne pločice (22) 1 ploče za pjenu (21) nalazi izbočena membrana.
A compound of Formula I: and pharmaceutically acceptable solvates thereof, wherein Ar1 is unsubstituted thiophen-2-yl, unsubstituted phenyl, or 4-fluorophenyl; 
[image] i njegovi farmaceutski prihvatljivi solvati, naznačen time da Ar1 je nesupstituirani tiofen-2-il, nesupstituirani fenil, ili 4-fluorofenil;
A host cell containing the nucleic acid of claim 9. 
Stanica domaćin koja sadrži nukleinsku kiselinu sukladno patentnom zahtjevu 9.
allowing a compound of formula (I) to react in the presence of a compound of formula R1SR2 and a chlorine-containing reagent under conditions sufficient to make a compound of formula (II); and 
Rs g koji sadrži, omogućavanje spoju formule (1): id da reagira u prisutnosti smjese spoja formule R,SR> i trikloroizocijanurne kiseline, pod uvjetima koji su dovoljni da se pripravi spoj formule (II); gdje
In some embodiments, the composition is in the form of a pill, tablet, capsule, gelcap, liquid, or emulsion. In yet some further embodiments, the pill, tablet, capsule, or gelcap further comprises an enteric coating. 
(ii) u obliku pilule, tablete, kapsule, gel kapsule, tekuća, ili emulzija, opcionalno pri čemu je spomenuta pilula, tableta, ili gel kapsula koja dalje ima enteričan premaz; i/ili
NMR are recorded at 400 MHz in CDCl3, unless otherwise noted. 
NMR su zapisani pri 400 MHz u CDCL, ako nije navedeno drugačije.
In order to separate the isomers, the mixture is treated with R (+) Mosher's acid, in the presence of oxalyl chloride and dimethylaminopyridine (DMAP) in dichloromethane to give a pair of diastereoisomeric esters (VII) (of which only one diastereoisomer is shown) which can then be separated using HPLC. 
Da bi se odijelili izomeri, smjesa se tretira sa R (+) Mosher-ovom kiselinom u prisutnosti oksalil klorida i dimetilaminopiridina (DMAP) u diklorometanu dajući par dijastereoizomernih estera (VII) (od kojih je prikazan samo jedan dijastereoizomer) koji se mogu odijeliti uporabom HPLC.
Preferably, the generation unit is a logic circuit which is programmable according to firmware supplied from the outside. 
Sustav za pružanje informacija o položaju prema bilo kojem zahtjevu od 1 do 7, naznačen time da je jedinica za generiranje signala logički sklop koji se može programirati u skladu s firmwareom koji je dobavljn izvana
As such, the present invention provides methods of reducing antipsychotic induced weight gain induced by atypical antipsychotic medications in a patient. 
Spoj slijedeće strukture: r ili njegova farmaceutski prihvatljiva sol, za uporabu u postupku smanjenja antipsihotički induciranog dobivanja na težini.
detecting or quantifying the binding of said second binding agent to the DNA base in the body fluid sample; and 
(lili) otkrivanje ili kvantificiranje vezivanja navedenog drugog sredstva za vezanje za bazu DNK u uzorku tjelesne tekućine; i
The apparatus of claim 11, comprising a calcium ammonium nitrate production section, said calcium ammonium nitrate production section comprising an inlet for ammonium nitrate in fluid communication with an outlet for ammonium nitrate from the ammonium nitrate section, wherein the calcium ammonium nitrate production section comprises a granulation section having an outlet for a third off-gas in fluid communication with a gas inlet of the off-gas treatment section. The apparatus of claim 11 wherein the finishing section of (a) has an inlet for air. 
Sustav prema bilo kojem od zahtjeva 9-13, koji sadrži sekciju proizvodnje kalcij amonijevog nitrata (CAN), spomenuta sekcija CAN proizvodnje sadrži ulaz za amonijev nitrat u komunikaciji fluida s izlazom za amonijev nitrat iz sekcije amonijevog nitrata, pri čemu sekcija CAN proizvodnje sadrži sekciju granulacije koja ima izlaz za ispareni plin u komunikaciji fluida s ulazom plina sekcije završne obrade.
In a second sub-aspect, the non-nucleophilic base is triethylamine. 
Postupak iz patentnog zahtjeva 4, u kome je ne-nukleofilna baza trietilamin.
Returning the filtered water to said at least one containing means; 
najmanje jedno sredstvo za filtriranje (3) koje filtrira strujanje vode koja sadrži nataložene čestice;
Oral administration of the compound required a higher dosage of the inhibitor and led to a less-marked, but still significant reduction of the tumor weight and 25% long-term survivors as compared with the saline-treated control group. 
Oralna primjena spoja zahtjeva veću dozu inhibitora i vodi do manje, ali još značajne redukcije težine tumora 1 25 % dugoročnih preživjelih u usporedbi s kontrolnom skupinom tretiranom fiziološkom otopinom.
A compound or a pharmaceutically acceptable salt thereof for use according to claim 4, wherein the BACE1 mediated disorder or disease is selected from the group consisting of a neurodegenerative disorder, cognitive decline, cognitive impairment, dementia, and disease characterized by the production of B-amyloid deposits or neurofibrillary tangles. 
Spoj, ili njegova farmaceutski prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 4, gdje se poremećaj ili bolest povezanu s BACE1 bira iz skupine koju čine neurodegenerativni poremećaj, slabljenje kognitivnih funkcija, kognitivni deficit, demencija, naznačen time što je za bolest karakteristična proizvodnja B-amiloidnih naslaga ili neurofibrilarnih klupka.
The compound according to any of claims 1-5, wherein the compound is a pharmaceutically acceptable salt of the anion chosen from chloride, bromide, iodide, sulfate, bisulfate, carbonate, bicarbonate, phosphate, hydrogen sulfonate, p-toluenesulfonate, methansulfonate, formate, acetate, propionate, butyrate, pyruvate, lactate, oxaleta, malonate, maleate, succinate, tartrate, fumarate, glycolate, or citrate. 
Pripravak u skladu s bilo kojim od patentnih zahtjeva 10 do 14, naznačen time što je spoj farmaceutski prihvatljiva sol aniona koji se bira između klorida, bromida, jodida, sulfata, bisulfata, karbonata, bikarbonata, fosfata, hidrogensulfonata, p-toluensulfonata, metansulfonata, formijata, acetata, propionata, butirata, piruvata, laktata, oksalata, malonata, maleata, sukcinata, tartarata, fumarata, glikolata ili citrata.
In dependence of the materials used as the RIS such appropriate solvent may be water or an organic solvent selected from the group consisting of petrol, ligroin, white spirit, kerosene and naphtha. 
Kemijski sustav prema patentnom zahtjevu 5, naznačen time, da otapalo za RIS jest voda ili organsko otapalo odabrano iz skupine koja se sastoji od benzina, ligroina, terpentina, kerozina i nafte.
the dip-moulding stage (12, 13) in which a resin is coated and cured on said formers (4) to form said gloves (2); 
stanicu (12, 13) za oblikovanje uranjanjem u kojoj se smola nanosi na navedene kalupe (4) i stvrdnjava na njima da bi se oblikovale spomenute rukavice (2);
A container according to any preceding claim, wherein the distance between the upper surface of the denesting area and the base of the tray is shorter than the distance between the upper surface of the flange and the base. 
Posuda prema patentnom zahtjevu 7, pri čemu je razmak između gornje površine zone za odvajanje i osnove posude manji od razmaka između gornje površine prirubnice i osnove.
A portable service bar according to claim 1 or 2, characterized in that the side walls and the front wall are arranged to be placed in an open position ready for use wherein each side wall is arranged essentially perpendicular to the front wall. 
Prijenosno uslužno mjesto prema zahtjevu 1 ili 2, naznačeno time da su u radnom položaju kada je spremno za korištenje, bočne stranice (4) i prednja stranica (2) postavljene tako da su postavljene u otvoreni položaj pri čemu je svaka bočna stranica (4) postavljena uglavnom okomito na prednju stranicu (2).
Intravenous formulation according to claim 3, wherein the inositol phosphate is myo -inositol hexaphosphate. 
Pripravak za uporabu prema zahtjevu 4, gdje inozitol fosfat jest myo-inozitol heksafosfat.
Composition for use according to any one of the preceding claims, wherein said lipophilic compound is selected from among saturated, unsaturated or hydrogenated long chain alcohols, saturated, unsaturated or hydrogenated fatty acids, salts thereof, esters or amides, mono-, di- or triglycerides of fatty acids, polyethoxylated derivatives thereof, waxes, ceramides, cholesterol, cholesterol derivatives or mixtures thereof. 
Pripravak prema prethodnim zahtjevima, gdje se lipofilni spojevi odabiru između zasićenih, nezasićenih ili hidrogeniranih dugolančanih alkohola, zasićenih, nezasićenih ili hidrogeniranih masnih kiselina, njihovih soli, estera ili amida, mono-, di- ili triglicerida masnih kiselina, njihovih polietoksiliranih derivata, voskova, ceramida, kolesterola, derivata kolesterola ili njihovih mješavina.
A fifth type of antikine antibody has a binding specificity similar or identical to 18P7E and binds to at least two, or three CC chemokines selected from the group consisting of CCL3/MIP-1a, CCL4/MIP-1B, and CCL5/RANTES. 
Monoklonsko protutijelo, ili njegov fragment koji veže antigen, u skladu s patentnim zahtjevom 1, naznačeno time, da se veže na najmanje tri CC kemokina odabrana iz skupine koja se sastoji od CCL3/MIP-1a, CCLA/MIP-IP, i CCLS/RANTES, a koji se ne veže to CCL2/MCP-I.
at collar 23, even though only the outer sealing has been shown. 
na prstenu 23, iako je prikazana samo vanjska brtva.
The nonwoven fabric according to claim 9, wherein the units are arranged in rows. 
Netkani materijal prema zahtjevu 7, naznačen time da su prve jedinice raspoređene u redovima.
A compound of formula (I), or a pharmaceutically acceptable salt thereof; 
1. < Spoj, naznačen time, da ima sljedeću Formulu (1), ili njegova farmaceutski prihvatljiva sol:
The peptide according to any of claims 1 to 3, wherein the peptide includes non-peptide bonds. 
Peptid u skladu s patentnim zahtjevom 1 ili 2, pri čemu peptid uključuje nepeptidne veze.
The composition of claim 8, wherein said composition is orally bioavailable. 
Sastav iz patentnog zahtjeva 8, pri čemu je navedeni sastav oralno bioraspoloživ.
N CH CF A compound of formula I, N-oxide, addition salt, quaternary amine, or a stereochemically isomeric form thereof; 
Spoj s formulom (1), N-oksid, adicijska sol, kvaterni amin, ili metalni kompleks, ili njihov stereokemijski izomerni oblik;
an anion exchange membrane separating the anode chamber and the cathode chamber; a catalytic reactor including a catalyst wherein the catalyst is activated carbon for reacting gaseous hydrogen and gaseous chlorine, said reactor having an inlet connected to the outlet of the cathode chamber and the outlet of the anode chamber and an outlet connected to at least one condensing chamber, wherein the outlet from the anode and the outlet from the cathode combine into a single pipeline to allow mixing of gaseous hydrogen and gaseous chlorine as they leave the electrolytic cell and before they enter the catalytic reactor; 
2. katalitički reaktor koji obuhvaća katalizator pri čemu katalizator je aktivni ugljen za reakciju plinovitog vodika i plinovitog klora; navedeni reaktor ima ulaz povezan s izlazom katodne komore i izlazom anodne komore i izlaz koji je povezan s najmanje jednom komorom za kondenzaciju; te pri čemu se izlaz iz anode i izlaz iz katode kombiniraju u jedan cjevovod, ili oba ulaze i isti cjevovod, kako bi se omogućilo miješanje plinovitog vodika i plinovitog klora dok napuštaju elektrolitičku ćeliju i prije nego što uđu u katalitički reaktor; i
The dental post according to at least one of the claims 1 to 4, characterized in that photochromic particles are embedded in said post. 
Zubni potporanj u skladu s najmanje jednim od patentnih zahtjeva 1 do 11, naznačen time što je materijal koji apsorbira rendgenske zrake usađen u navedeni potporanj.
In some embodiments, the DE loop comprises an amino acid sequence according to the formula X23-G-R-G-X24, wherein (a) X23 is selected from the group consisting of V, P, F, I and L; and (b) X24 is selected from the group consisting of S, N and T. 
(1) serin na položaju 3 u petlji BC (SEQ ID NO: 34) je zamijenjen aminokiselinom koju se bira iz skupine kojučne A,C,DEF,H,1,K,L,N,Q,R, T, V, W te Y;
The use of item 167, wherein said drug that inhibits complement activity and said immunosuppressive drug are in a formulation suitable for concurrent administration to said mammal. 
Uporaba prema bilo kojem od zahtjeva 26 do 29, naznačena time, što je spomenuto anti-C5 antitijelo u formulaciji pogodnoj za stalnu primjenu kod spomenutog sisavca primatelja.
A formulation of any one of items 1 to 21, wherein said formulation is in the form of a gel, lotion, cream, spray, aerosol, ointment, emulsion, suspension, liposomal system, lacquer, patch, bandage, buccal tablet, sublingual tablet, suppository, vaginal dosage form or occlusive dressing. 
Formulacija prema bilo kojem od zahtjeva 1 do 12, naznačena time, da je navedena formulacija u obliku gela, losiona, kreme, spreja, aerosola, masti, emulzije, suspenzije, liposomnog sustava, laka, flastera, zavoja, bukalne tablete, sublingvalne tablete, čepića, vaginalnog doznog oblika ili okluzivnog zavoja, te poželjno u obliku gela.
Za is Val; and Qa is MeLeu, with the proviso that Rb is not H when Ya is MeLeu, or a pharmaceutically acceptable salt thereof.. 
Z je Val, Leu, MeVal ili MeLeu; te Q' je MeLeu, Y-hidroksi-MeLeu ili MeAla, ili njegova farmaceutski prihvatljiva sol.
In one embodiment of the present invention, the device is arranged in an array to carry out multiple PCRs. 
Mikro PCR uređaj prema zahtjevu 7, pri čemu je mikročip (10) postavljen u niz kako bi se provela višestruka lančana reakcija polimeraze.